Sultan Linjawi

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

Stephen Gough, Bruce W. Bode, Vincent Woo et al. · The Lancet Diabetes & Endocrinology · 2014 · 362 citations

Medicine, Pharmacology, Pharmacotherapy +15

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Sultan Linjawi, Bruce W. Bode, Louis Chaykin et al. · Diabetes Therapy · 2016 · 134 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial

Stephen Gough, Bruce W. Bode, Vincent Woo et al. · Diabetes Obesity and Metabolism · 2015 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Flexible eating and flexible insulin dosing in patients with diabetes: Results of an intensive self-management course

Julia Lowe, Sultan Linjawi, M. Mensch et al. · Diabetes Research and Clinical Practice · 2008 · 98 citations

Medicine, Endocrinology, Internal Medicine +16